Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

Company operates in the pharmaceutical and data centre sectors and is to expand it offerings to the electric vehicle battery ...